Alzheimer’s is a progressive neurological disorder that affects memory, thinking, and behavior. It worsens over time, leading ...

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS), a clinical-stage biopharmaceutical company, is set to showcase significant ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

A new study uncovers compelling evidence that even subtle heart issues may affect brain structure — potentially years before ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

Cognition may be just one phase of intelligence—as AI evolves, thought itself begins to dissolve into something more fluid, ...

Discover how Alzheimer's disease progresses from mild cognitive changes to severe symptoms, with explanations of each stage ...

This highlights that a general slowdown in processing might underlie broader cognitive and linguistic changes with age, rather than a specific challenge in memory retrieval for words. While the ...